New hope for recurrent ovarian and uterine cancer? early trial launches
NCT ID NCT06107868
First seen Jan 05, 2026 · Last updated May 09, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug (RP-6306) combined with two standard chemotherapies for people with recurrent ovarian or uterine cancer that has a specific gene change (TP53 mutation). The main goals are to find the safest dose and see if the combination can shrink tumors or slow the disease. Only 6 participants are enrolled, so results will be very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.